CHS presents information on effects of pre-diabetic condition on quality of life
PRINCETON, N.J. Consumer Health Sciences on Tuesday presented data at the 15th Annual Conference of the International Society for Quality of Life Research, Montevideo, Uruguay, that demonstrated the significant impact having pre-diabetes has on the quality of life and work productivity of patients.
The results demonstrated that pre-diabetic patients have a lower health related quality of life and higher levels of work productivity impairment when compared to a healthy non-diabetic population. The presentation further quantified the loss of work productivity as 5.6 weeks per year for each pre-diabetic patient compared to their healthy counterparts.
“These results truly highlight the need for better diagnosis and new treatments for patients with pre-diabetes as a way to help slow the growing epidemic of diabetes and its impact on the patient and society,” said Michael Fronstin, chief operating officer of Consumer Health Sciences. “Less than 40 percent of all pre-diabetic patients are even aware of their condition and therefore can’t take the steps necessary to prevent it from progressing to a full diabetes diagnosis.”
The results were based on an analysis of 63,000 patients from the 2007 U.S. National Health and Wellness Survey. Pre-diabetic patients were identified and compared to patients with and without diabetes using validated patient reported health outcomes scales. Further analyses of these pre-diabetes patients are being conducted by the scientific team at Consumer Health Sciences to more deeply understand the demographic, attitudinal and epidemiology differences of this patient group.
FDA grants conditional approval to generic version of Wyeth’s Effexor
PITTSBURGH The Food and Drug Administration has given tentative approval to a generic version of Wyeth Pharmaceutical’s Effexor XR, an antidepressant.
Mylan announced the FDA decision Monday for its version of the drug, known generically as venlafaxine hydrochloride. Mylan plans to sell the extended-release capsules in 37.5 mg, 75 mg and 150 mg formulations.
The branded version of the drug had sales of $3 billion during the 12 months ending Sept. 30, according to IMS Health.
Interpol seizes more than $6 million in counterfeit prescription drugs in Asia
NEW YORK More than $6 million in counterfeit drugs were seized in an international Interpol sting as part of an investigation lasting five months.
The bust, called Operation Storm, netted $6.65 million in counterfeits of drugs for malaria, HIV and tuberculosis in Singapore, Myanmar, Vietnam, Thailand, Laos, Cambodia and China.
The international law-enforcement agency arrested 27 people in the sting.